ARTICLE | Company News
Quest Diagnostics sales and marketing update
January 18, 2010 8:00 AM UTC
Quest launched its blood-based ColoVantage colorectal cancer diagnostic in the U.S. The test is based on the methylated septin 9 (SEPT9) biomarker from Epigenomics AG (Xetra:ECX, Berlin, Germany). Q...